MAST CELL ACTIVATION DISORDER IDIOPATHIC

Clinical trials for MAST CELL ACTIVATION DISORDER IDIOPATHIC explained in plain language.

Never miss a new study

Get alerted when new MAST CELL ACTIVATION DISORDER IDIOPATHIC trials appear

Sign up with your email to follow new studies for MAST CELL ACTIVATION DISORDER IDIOPATHIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Pain relief drug for mast cell disorder fails to reach goal

Symptom relief Terminated

This study tested whether FSD201 could reduce daily pain in adults with chronic widespread pain caused by mast cell activation syndrome. Only 2 people enrolled before the trial was stopped early. Participants took FSD201 or a placebo for up to 56 days and reported their pain leve…

Matched conditions: MAST CELL ACTIVATION DISORDER IDIOPATHIC

Phase: PHASE2 • Sponsor: Quantum Biopharma • Aim: Symptom relief

Last updated May 14, 2026 12:06 UTC

MAST CELL ACTIVATION DISORDER IDIOPATHIC

Get alerted when new MAST CELL ACTIVATION DISORDER IDIOPATHIC trials appear

Pain relief drug for mast cell disorder fails to reach goal